NCT00052611View on ClinicalTrials.gov

Celecoxib in Preventing Cancer in Patients With Oral Leukoplakia and/or Head and Neck Dysplasia

PHASE2CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

June 30, 2002

Primary Completion Date

March 31, 2005

Study Completion Date

March 31, 2005

Conditions
Head and Neck Cancer
Interventions
DRUG

Celecoxib

Trial Locations (3)

02114

Massachusetts General Hospital Cancer Center, Boston

02115

Brigham and Women's Hospital, Boston

Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Boston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Dana-Farber Cancer Institute

OTHER

NCT00052611 - Celecoxib in Preventing Cancer in Patients With Oral Leukoplakia and/or Head and Neck Dysplasia | Biotech Hunter | Biotech Hunter